On April 9, 2018, OBIO hosted Pfizer Global for a workshop and partnering day at ONRamp in the Banting Institute.
Recapping OBIO Does Indian Street Food: Third Annual Pre-RESI Networking Event
Showcasing Ontario's High Potential Companies: Niagara Emerging Health Sciences Company Forum
OBIO Health Economics Day: A Review
On October 24th, OBIO hosted Health Economics Day workshop in partnership with St. Michael’s Hospital.
The workshop took place in the auditorium at the Li Ka Shing Knowledge Institute and featured four sessions: a moderated panel discussion with four panellists, followed by three presentations by three health economics experts.
OBIO blog: Updating the Innovation Supercluster Shortlist
Recently, the Minister of Innovation, Science and Economic Development launched a cross country tour to introduce the nine supercluster proposals that have been shortlisted by the federal government for the Innovation Superclusters Initiative.
Grant Burns, OBIO's Public Affairs and Communications Manager, has listed the 9 proposals and provided commentary and analysis on how they relate to the health technology sector.
Be in the Know with OBIO: Getting Your Foot in the Door with Pharma - Alexion Day Reflections
Be in the Know: An Opportunity for Medical Device Companies: CE Marking and Coming EU Regulatory Changes
OBIO's Dr. Klaus Fiebig, VP Strategic Programs, recently attended an insightful workshop on the upcoming regulatory changes affecting the CE mark. Obtaining the CE mark is a "mandatory hurdle" to access the $56B EU market, and the new regulatory changes present an opportunity for medical device companies.
Should these changes adjust your CE mark milestones? Read the Klaus' analysis and decide.
Raising Capital in the Digital Health Industry: Lessons from FCA Venture Partners
OBIO Comments to Health Canada re: PMPRB consultation
Anchor companies and 'sticky capital': Biotechnology Focus
In the latest issue of Biotechnology Focus, OBIO President and CEO Gail Garland contributed a special report.
Anchor Companies and 'Sticky Capital': A prescription for attracting bioscience investment to Ontario